Full Coverage

Pfizer invests in 3SBio's SSGJ-707 drug for cancer treatment

Pfizer Secures Global Licensing Rights Outside China for 3SBio’s Dual-Target Cancer Therapy SSGJ-707

14 hours ago

BioWorld MedTech

Pfizer’s $6.15B 3Sbio deal tops May’s biopharma activity

21 hours ago

By Amanda Lanier

Fierce Pharma Asia—Pfizer CEO talks bispecific deal; Otsuka's kidney disease win; Novartis-MSN Entresto feud

5 days ago

By Angus Liu

Pfizer CEO talks Chinese due diligence, ADC synergies to justify $6B bet on 'fabulous' bispecific

8 days ago

By Paul Taylor

BioWorld MedTech

3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

21 hours ago

Pfizer Secures Global Licensing Rights Outside China for 3SBio’s PD-1 and VEGF Targeting Antibody SSGJ-707

5 days ago

Pfizer Secures Global Rights Outside China for 3SBio’s Dual-Target Cancer Therapy SSGJ-707

2 days ago

Pfizer Secures Global Licensing Rights for 3SBio’s Dual-Target Cancer Therapy Excluding China

4 days ago

Search

Clear search

Close search

Google apps

Main menu